Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Do Corticosteroids Reduce Mortality or Progression to Severe Disease for Non-Oxygen Requiring Patients Infected With COVID-19?

**TAKE-HOME MESSAGE**

In patients infected with COVID-19 not requiring supplemental oxygen, systemic corticosteroids are associated with a small increase in mortality and progression to severe disease.

**EBEM Commentators**

Dhimitri A. Nikolla, DO
Brett R. Forehand, MD, PhD
Department of Emergency Medicine,
Allegheny Health Network–Saint Vincent Hospital, Erie, PA

Jestin N. Carlson, MD, MS, Alan Jones, MD, and Michael Gottlieb, MD, serve as editors of the SRS series.

---

**METHODS**

**DATA SOURCES**

Two independent investigators searched PubMed, Embase, Web of Science, and medRxiv databases from December 2019 to May 2021 using the terms COVID-19 (or synonyms) AND corticosteroids (or synonyms) OR dexamethasone OR methylprednisolone OR hydrocortisone. The authors also examined the relevant article and related citation lists from PubMed. They did not restrict by country or publication language; however, they also did not report searching gray literature. The authors performed the search in accordance with the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) guidelines.1

**STUDY SELECTION**

Two independent investigators selected randomized controlled trials and prospective or retrospective observational studies that used propensity score matching. They included studies evaluating the effectiveness of systemic corticosteroids in COVID-19 patients who did not require oxygen at the time of infection.

---

**RESULTS**

Select outcome measures for corticosteroids versus no corticosteroids.

| Outcome                          | No. of Studies | Corticosteroids   |
|----------------------------------|----------------|-------------------|
| Mortality                        |                | Yes, n (%)        |
|                                  | 2 RCT, 1 PSM   | 91/586 (15.5)     |
|                                  |                | 145/1131 (12.8)   |
|                                  |                | 1.35 (1.01, 1.79) |
| Progression to severe disease    | 2 PSM          | 11/90 (12.2)      |
|                                  |                | 2/90 (2.2)        |
|                                  |                | 5.97 (1.27, 27.99)|

*Although the review included 7 studies in total, not all evaluated mortality or progression to severe disease.

The authors screened 2,990 studies and reviewed 145 full-text articles. After exclusions, they included 7 studies: 4 randomized controlled trials and 3 retrospective propensity score matching studies. These studies included 2,214 laboratory-confirmed COVID-19 patients not requiring supplemental oxygen, 853 receiving systemic corticosteroid treatment, and 1,381 without. Although 6 of the 7 studies examined methylprednisolone,6-11 the study that contributed the most patients to the meta-analysis used a 6 mg/day dose of oral or intravenous dexamethasone for 10 days.12

Systemic corticosteroid administration was associated with increased mortality and progression to severe disease (Table). In
enrollment or exposure. The authors examined the following outcomes: mortality, progression to severe disease, fever duration, viral clearance, and hospital length of stay. They excluded case reports, letters, editorials, and reviews. They also excluded studies evaluating inhaled or intranasal corticosteroids. A third reviewer resolved discrepancies.

**DATA EXTRACTION AND SYNTHESIS**

The authors reviewed studies using the National Health Commission of China or World Health Organization definitions for mild or moderate COVID-19. A single reviewer extracted the data, and a second reviewer verified the data independently. They assessed the risk of bias for randomized controlled trials using the Cochrane Risk of Bias tool and methodological quality for propensity score matching observational studies using the Risk of Bias Assessment Tool for Non-randomized Studies. Two authors performed the quality assessment separately, with disagreements addressed by consensus in the presence of a third reviewer. They calculated pooled odds ratios using a random-effects model and estimated heterogeneity between studies with $I^2$ statistics.

Commentary

Not all patients with COVID-19 benefit from systemic corticosteroids. Systemic corticosteroids lower the 28-day all-cause mortality in critically ill COVID-19 patients who require supplemental oxygen. However, a mortality benefit has not been observed in those who do not require supplemental oxygen. Furthermore, this review suggests that systemic corticosteroids are harmful in this nonhypoxemic cohort of COVID-19 patients, associated with higher mortality and progression to severe disease. Although uncommon with COVID-19, the authors suggest that corticosteroids may increase the risk of secondary bacterial infections.

However, this study has several limitations. First, this review excluded inhaled corticosteroids, and the route of administration may be significant. Inhaled budesonide has been shown to reduce recovery time and the need for urgent medical care among nonhospitalized COVID-19 patients. However, this recovery time benefit is not consistent among other inhaled corticosteroids, particularly ciclesonide.

Additionally, despite a large number of patients, this meta-analysis includes a small number of studies, and all the studies had either a high or unclear risk of bias, which might compromise the validity of the results. Furthermore, the meta-analysis included propensity score matching observational studies, making the results susceptible to confounding. Next, the review does not address COVID-19 patients with concurrent asthma or chronic obstructive pulmonary disease exacerbations in whom systemic corticosteroids remain indicated despite normoxia.

Chronic systemic corticosteroid use is a risk factor for severe COVID-19 infection in, for example, asthma and chronic liver disease patients, therefore, possible selection of these high-risk patients into the corticosteroid groups in the propensity score matching studies could have biased the results against corticosteroids. Lastly, the authors excluded studies from their analysis in which no patients died or progressed to severe disease in either treatment group. This exclusion may have introduced some selection bias where only studies with sicker patients were assessed, and sicker patients may have been more likely to get corticosteroids in the propensity score matching studies, making the corticosteroid group appear worse. In addition, the pooled mortality in this review was 13.7%, which is higher than the 1.2% to 7.0% overall COVID-19 mortality found in other studies.

Therefore, illness severity may have confounded the results. Nevertheless, the a priori choice of mortality as an end point in these less critically ill patients with COVID-19 infections is less logical than in sicker cohorts.

1. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151:264-269.

2. China National Health Commission. Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment (7th edition). Updated March 4, 2020.
1. Ma Y, Zeng H, Zhan Z, et al. Corticosteroids treatment of patients with COVID-19 pneumonia: a propensity score-based analysis. Shock. 2020;54:638-643.
2. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693-704.
3. Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330-1341.
4. Sahu AK, Mathew R, Bhat R, et al. Steroids use in non-oxygen requiring COVID-19 patients: a systematic review and meta-analysis. QJM. 2021;114:455-463.
5. Russell CD, Fairfield CJ, Drake TM, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe. 2021;2:e354-e365.
6. Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide for COVID-19 in adults with symptomatic COVID-19: a multicenter, single-Blind, randomized control trial. J Clin Pharmocol. 2021;100:116-126.
7. Li Q, Li W, Jin Y, et al. Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: a retrospective cohort study. Infect Dis Ther. 2020;9:823-836.
8. Liang MY, Chen P, He M, et al. Corticosteroids treatment of patients with coronavirus disease 2019 (COVID-19; Metcovid); a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021;72:e373-e381.
9. Jeronimo CMP, Farias MEL, Val FFA, et al. The Cochrane Collaboration’s tool for assessing the risk of bias in randomised trials. BMJ. 2011;343:d5928.
10. Yuan M, Xu X, Xia D, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66:408-414.
11. Li Q, Park JE, Lee YJ, et al. Efﬁcacy of inhaled ciclesonide for the treatment of COVID-19 in adult outpatients: a multicenter retrospective study in Hunan, China. Front Pharmacol. 2020;11:1198.
12. Yuan M, Xu X, Xia D, et al. Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score matching study. Curr Med Sci. 2021;41:24-30.
13. O’Horo JC, Cehan JR, Cahn EJ, et al. Outcomes of COVID-19 with the Mayo Clinic model of care and research. Mayo Clin Proc. 2021;96:601-618.
14. Li Q, Li W, Jin Y, et al. Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: a retrospective cohort study. Infect Dis Ther. 2020;9:823-836.